Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. The company operates in two segments, Reservoir Description and Production Enhancement. The Reservoir Description segment includes the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and petroleum products; and proprietary and joint industry studies. The Production Enhancement segment offers services and products relating to reservoir well completions, perforations, stimulations, and production. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. The company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. Core Laboratories N.V. was founded in 1936 and is based in Amstelveen, the Netherlands.
IPO Year: 2023
Exchange: NYSE
Website: corelab.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/30/2023 | $22.00 → $21.00 | Neutral → Sell | Citigroup |
4/18/2023 | $21.50 | Neutral → Underperform | BofA Securities |
1/9/2023 | Underperform → Neutral | BofA Securities | |
10/7/2022 | $24.00 → $17.00 | Sell → Neutral | Citigroup |
9/26/2022 | $20.00 | Equal-Weight → Underweight | Morgan Stanley |
4/18/2022 | $19.50 → $21.30 | Neutral → Underweight | Piper Sandler |
1/18/2022 | $32.00 → $30.00 | Equal-Weight | Morgan Stanley |
12/7/2021 | $34.00 → $32.00 | Equal-Weight | Morgan Stanley |
10/18/2021 | $36.00 → $32.00 | Neutral → Underperform | BofA Securities |
10/11/2021 | $37.00 → $34.00 | Equal-Weight | Morgan Stanley |
Core Laboratories (NYSE:CLB) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.21 by 4.76 percent. This is a 4.76 percent increase over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $130.577 million which missed the analyst consensus estimate of $132.170 million by 1.21 percent. This is a 2.11 percent increase over sales of $127.881 million the same period last year.
B of A Securities analyst Chase Mulvehill maintains Core Laboratories (NYSE:CLB) with a Underperform and lowers the price target from $16 to $15.
Piper Sandler analyst Luke Lemoine maintains Core Laboratories (NYSE:CLB) with a Neutral and lowers the price target from $18 to $17.
Stifel analyst Stephen Gengaro maintains Core Laboratories (NYSE:CLB) with a Hold and raises the price target from $17 to $18.
U.S. stocks were lower, with the Dow Jones falling over 600 points on Thursday. Shares of Sanofi SA (NASDAQ:SNY) rose sharply during Thursday's session following better-than-expected first-quarter earnings. Sanofi reported first-quarter operating income of 2.8 billion euros, down 14.7% Y/Y and 4.2% on constant currency. The French drugmaker reported adjusted EPS of 97 cents (1.78 euros), beating the consensus estimate of 94 cents, according to data from Benzinga Pro. Sanofi shares climbed 5.5% to $49.15 on Thursday. Here are some other big stocks recording gains in today's session. P.A.M. Transportation Services, Inc. (NASDAQ:PTSI) jumped 19.8% to $17.42 after the company ann
Core Laboratories (NYSE:CLB) reported quarterly Adj earnings of $0.19 per share which beat the analyst consensus estimate of $0.16 by 18.75 percent. The company reported quarterly sales of $129.637 million which beat the analyst consensus estimate of $124.442 million by 4.17 percent. This is a 1.00 percent increase over sales of $128.356 million the same period last year.
B of A Securities analyst Chase Mulvehill maintains Core Laboratories (NYSE:CLB) with a Underperform and lowers the price target from $17 to $16.
New Cannabis CEOs, CFOs And Other Appointments Canadian medical cannabis giant Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB) announced on Tuesday that Simona King, a former executive of Bristol Myers-Squibb (NYSE:BMY) has been named the company's new CFO, replacing Glen Ibbott at the new role. Aurora simultaneously announced the completion of its consolidation of the common shares of the company on a 10 to 1 basis. The common shares will begin trading on a post-consolidation basis on the NASDAQ Capital Market and the Toronto Stock Exchange (TSX) under the symbol “ACB” at the opening of trading on Tuesday. Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) (FSE: 6CQ) kicked off the month by annou
Stifel analyst Stephen Gengaro maintains Core Laboratories (NYSE:CLB) with a Hold and lowers the price target from $21 to $17.
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
10-Q - Core Laboratories Inc. /DE/ (0001958086) (Filer)
8-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
11-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
S-8 - Core Laboratories Inc. /DE/ (0001958086) (Filer)
SD - Core Laboratories Inc. /DE/ (0001958086) (Filer)
8-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
10-Q - Core Laboratories Inc. /DE/ (0001958086) (Filer)
8-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
ARS - Core Laboratories Inc. /DE/ (0001958086) (Filer)
8-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SECOND QUARTER REVENUE OF $130.6 MILLION, UP SLIGHTLY SEQUENTIALLY AND YEAR-OVER-YEARSECOND QUARTER OPERATING INCOME OF $16.0 MILLION; EX-ITEMS, $16.4 MILLION, UP 10% SEQUENTIALLY AND 5% YEAR-OVER-YEAR SECOND QUARTER OPERATING MARGINS, EX-ITEMS, OF 13% SECOND QUARTER GAAP EPS OF $0.19; EX-ITEMS, $0.22, UP 16% SEQUENTIALLY AND 5% YEAR-OVER-YEARSECOND QUARTER FREE CASH FLOW OF $14.3 MILLION; NET DEBT REDUCED BY $15.8 MILLIONCOMPANY ANNOUNCES Q3 2024 QUARTERLY DIVIDENDHOUSTON, July 24, 2024 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported second quarter 2024 revenue of $130,600,000. Core's operating income was $16,000,000, with diluted earnin
NEWPORT BEACH, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Gateway Group ("Gateway"), a leading financial communications and digital media advisory firm, today announced the initial sponsor list and latest presenting companies for its annual Gateway Conference taking place at the Four Seasons Hotel in San Francisco on September 4th and 5th. Conference SponsorshipThe Gateway Conference is sponsored by leading firms servicing the financial community. The event provides a rich environment for business development and an effective marketing platform to reach key corporate decision makers. Sponsorships are currently available in the Gold, Silver, and Bronze levels. For additional inform
HOUSTON, June 25, 2024 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will broadcast its second quarter 2024 conference call over the Internet at 7:30 a.m. CDT / 8:30 a.m. EDT on July 25, 2024. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on July 24th and may be accessed through the Company's website at www.corelab.com. To participate in the live webcast, simply log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those who are not available to listen to the live webcast, a Podcas
NEWPORT BEACH, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Gateway Group ("Gateway"), a leading financial communications and digital media advisory firm, today announced the preliminary list of presenting companies for its annual Gateway Conference taking place at the Four Seasons Hotel in San Francisco on September 4th and 5th. Celebrating 25 years of connecting leading growth companies with global capital markets audiences, Gateway is bringing back its flagship conference in person for the first time since 2019. Over the past decade, the Gateway Conference has served as a vital platform for hundreds of companies, both public and private, across sectors such as technology, cleantech, cons
FIRST QUARTER REVENUE OF $129.6 MILLION, UP MODESTLY SEQUENTIALLY AND YEAR-OVER-YEARFIRST QUARTER OPERATING INCOME OF $8.6 MILLION; EX-ITEMS, $14.9 MILLION, FLAT SEQUENTIALLY, UP 3% YEAR-OVER-YEAR FIRST QUARTER OPERATING MARGINS, EX-ITEMS, OF 12% FIRST QUARTER GAAP EPS OF $0.07; EX-ITEMS, $0.19, FLAT SEQUENTIALLY AND YEAR-OVER-YEARFIRST QUARTER FREE CASH FLOW OF $2.5 MILLIONCOMPANY ANNOUNCES Q2 2024 QUARTERLY DIVIDENDHOUSTON, April 24, 2024 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported first quarter 2024 revenue of $129,600,000. Core's operating income was $8,600,000, with diluted earnings per share ("EPS") of $0.07, all in accordance w
HOUSTON, March 25, 2024 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will broadcast its first quarter 2024 conference call over the Internet at 7:30 a.m. CDT / 8:30 a.m. EDT on April 25, 2024. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on April 24th and may be accessed through the Company's website at www.corelab.com. To participate in the live webcast, simply log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those who are not available to listen to the live webcast, a Po
FOURTH QUARTER REVENUE OF $128.2 MILLION, UP 2% SEQUENTIALLYFOURTH QUARTER OPERATING INCOME OF $14.6 MILLION; EX-ITEMS, $15.0 MILLION, DOWN 6% SEQUENTIALLY FOURTH QUARTER OPERATING MARGINS, EX-ITEMS, OF 12% FOURTH QUARTER GAAP EPS OF $0.14; EX-ITEMS, $0.19, DOWN 14% SEQUENTIALLY FOURTH QUARTER FREE CASH FLOW OF $16.7 MILLIONFOURTH QUARTER DEBT REDUCED BY $15.0 MILLION OR OVER 8% COMPANY ANNOUNCES Q1 2024 QUARTERLY DIVIDENDFULL YEAR REVENUE OF $510.0 MILLION, UP 4%FULL YEAR OPERATING INCOME OF $54.6 MILLION; EX-ITEMS, $61.2 MILLION, UP 36%FULL YEAR GAAP EPS OF $0.86; EX-ITEMS, EPS OF $0.80, UP 40%HOUSTON, Jan. 31, 2024 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab",
HOUSTON, Jan. 2, 2024 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will broadcast its fourth quarter 2023 conference call over the Internet at 7:30 a.m. CST / 8:30 a.m. EST on February 1, 2024. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on January 31st and may be accessed through the Company's website at www.corelab.com. To participate in the live webcast, simply log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those who are not available to listen to the live webcast, a P
HOUSTON, Oct. 9, 2023 /PRNewswire/ -- Halliburton Company (NYSE:HAL) and Core Laboratories Inc. (NYSE:CLB) today announced a strategic collaboration in the U.S. to compress the delivery time of cutting-edge comprehensive digital rock data solutions from months to weeks, even while full petrophysical laboratory measurements are in progress. This collaboration combines Core Lab's industry-leading expertise in reservoir description and optimization technologies with Halliburton's specialization in pore-scale digital rock analysis. The collaboration facilitates the seamless inte
HOUSTON, Oct. 2, 2023 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will broadcast its third quarter 2023 conference call over the Internet at 7:30 a.m. CDT / 8:30 a.m. EDT on November 2, 2023. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on November 1st and may be accessed through the Company's website at www.corelab.com. To participate in the live webcast, simply log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those who are not available to listen to the live webcast, a Po
Citigroup downgraded Core Labs from Neutral to Sell and set a new price target of $21.00 from $22.00 previously
BofA Securities downgraded Core Labs from Neutral to Underperform and set a new price target of $21.50
BofA Securities upgraded Core Labs from Underperform to Neutral
Citigroup upgraded Core Labs from Sell to Neutral and set a new price target of $17.00 from $24.00 previously
Morgan Stanley downgraded Core Labs from Equal-Weight to Underweight and set a new price target of $20.00
Piper Sandler downgraded Core Labs from Neutral to Underweight and set a new price target of $21.30 from $19.50 previously
Morgan Stanley reiterated coverage of Core Laboratories with a rating of Equal-Weight and set a new price target of $30.00 from $32.00 previously
Morgan Stanley reiterated coverage of Core Laboratories with a rating of Equal-Weight and set a new price target of $32.00 from $34.00 previously
BofA Securities downgraded Core Labs from Neutral to Underperform and set a new price target of $32.00 from $36.00 previously
Morgan Stanley reiterated coverage of Core Laboratories with a rating of Equal-Weight and set a new price target of $34.00 from $37.00 previously
SECOND QUARTER REVENUE OF $130.6 MILLION, UP SLIGHTLY SEQUENTIALLY AND YEAR-OVER-YEARSECOND QUARTER OPERATING INCOME OF $16.0 MILLION; EX-ITEMS, $16.4 MILLION, UP 10% SEQUENTIALLY AND 5% YEAR-OVER-YEAR SECOND QUARTER OPERATING MARGINS, EX-ITEMS, OF 13% SECOND QUARTER GAAP EPS OF $0.19; EX-ITEMS, $0.22, UP 16% SEQUENTIALLY AND 5% YEAR-OVER-YEARSECOND QUARTER FREE CASH FLOW OF $14.3 MILLION; NET DEBT REDUCED BY $15.8 MILLIONCOMPANY ANNOUNCES Q3 2024 QUARTERLY DIVIDENDHOUSTON, July 24, 2024 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported second quarter 2024 revenue of $130,600,000. Core's operating income was $16,000,000, with diluted earnin
HOUSTON, June 25, 2024 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will broadcast its second quarter 2024 conference call over the Internet at 7:30 a.m. CDT / 8:30 a.m. EDT on July 25, 2024. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on July 24th and may be accessed through the Company's website at www.corelab.com. To participate in the live webcast, simply log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those who are not available to listen to the live webcast, a Podcas
FIRST QUARTER REVENUE OF $129.6 MILLION, UP MODESTLY SEQUENTIALLY AND YEAR-OVER-YEARFIRST QUARTER OPERATING INCOME OF $8.6 MILLION; EX-ITEMS, $14.9 MILLION, FLAT SEQUENTIALLY, UP 3% YEAR-OVER-YEAR FIRST QUARTER OPERATING MARGINS, EX-ITEMS, OF 12% FIRST QUARTER GAAP EPS OF $0.07; EX-ITEMS, $0.19, FLAT SEQUENTIALLY AND YEAR-OVER-YEARFIRST QUARTER FREE CASH FLOW OF $2.5 MILLIONCOMPANY ANNOUNCES Q2 2024 QUARTERLY DIVIDENDHOUSTON, April 24, 2024 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported first quarter 2024 revenue of $129,600,000. Core's operating income was $8,600,000, with diluted earnings per share ("EPS") of $0.07, all in accordance w
HOUSTON, March 25, 2024 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will broadcast its first quarter 2024 conference call over the Internet at 7:30 a.m. CDT / 8:30 a.m. EDT on April 25, 2024. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on April 24th and may be accessed through the Company's website at www.corelab.com. To participate in the live webcast, simply log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those who are not available to listen to the live webcast, a Po
FOURTH QUARTER REVENUE OF $128.2 MILLION, UP 2% SEQUENTIALLYFOURTH QUARTER OPERATING INCOME OF $14.6 MILLION; EX-ITEMS, $15.0 MILLION, DOWN 6% SEQUENTIALLY FOURTH QUARTER OPERATING MARGINS, EX-ITEMS, OF 12% FOURTH QUARTER GAAP EPS OF $0.14; EX-ITEMS, $0.19, DOWN 14% SEQUENTIALLY FOURTH QUARTER FREE CASH FLOW OF $16.7 MILLIONFOURTH QUARTER DEBT REDUCED BY $15.0 MILLION OR OVER 8% COMPANY ANNOUNCES Q1 2024 QUARTERLY DIVIDENDFULL YEAR REVENUE OF $510.0 MILLION, UP 4%FULL YEAR OPERATING INCOME OF $54.6 MILLION; EX-ITEMS, $61.2 MILLION, UP 36%FULL YEAR GAAP EPS OF $0.86; EX-ITEMS, EPS OF $0.80, UP 40%HOUSTON, Jan. 31, 2024 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab",
HOUSTON, Jan. 2, 2024 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will broadcast its fourth quarter 2023 conference call over the Internet at 7:30 a.m. CST / 8:30 a.m. EST on February 1, 2024. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on January 31st and may be accessed through the Company's website at www.corelab.com. To participate in the live webcast, simply log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those who are not available to listen to the live webcast, a P
HOUSTON, Oct. 2, 2023 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will broadcast its third quarter 2023 conference call over the Internet at 7:30 a.m. CDT / 8:30 a.m. EDT on November 2, 2023. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on November 1st and may be accessed through the Company's website at www.corelab.com. To participate in the live webcast, simply log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those who are not available to listen to the live webcast, a Po
REVENUE OF $127.9 MILLION; FLAT SEQUENTIALLY; UP 6% YEAR-OVER-YEAROPERATING INCOME OF $18.9 MILLION; EX-ITEMS, $15.6 MILLION, UP 8% SEQUENTIALLY; UP OVER 60% YEAR-OVER-YEAROPERATING MARGINS OF 15%; EX-ITEMS, OVER 12%, WITH YEAR-OVER-YEAR INCREMENTAL MARGINS EXCEEDING 85% GAAP EPS OF $0.48; EX-ITEMS, $0.21, UP 12% SEQUENTIALLY; UP 80% YEAR-OVER-YEARRESERVOIR DESCRIPTION INCREMENTAL MARGINS, EX-ITEMS, EXCEEDING 100% SEQUENTIALLY; EXCEEDING 80% YEAR-OVER-YEARFREE CASH FLOW OF $6.6 MILLIONAT-THE-MARKET EQUITY OFFERING PROGRAM TERMINATEDCOMPANY ANNOUNCES Q3 2023 QUARTERLY DIVIDENDHOUSTON, July 26, 2023 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") rep
HOUSTON, June 27, 2023 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will broadcast its second quarter 2023 conference call over the Internet at 7:30 a.m. CDT / 8:30 a.m. EDT on July 27, 2023. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on July 26th and may be accessed through the Company's website at www.corelab.com. To participate in the live webcast, simply log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those who are not available to listen to the live webcast, a Podc
REVENUE OF $128 MILLION; UP SLIGHTLY SEQUENTIALLY; UP 11% YEAR-OVER-YEAROPERATING INCOME OF $6.5 MILLION; EX-ITEMS OF $14.5 MILLION, FLAT SEQUENTIALLY; UP OVER 100% YEAR-OVER-YEAROPERATING MARGINS, EX-ITEMS, OF 11%, WITH YEAR-OVER-YEAR INCREMENTAL MARGINS EXCEEDING 55% GAAP EPS OF $0.05; EX-ITEMS, $0.19; UP OVER 130% YEAR-OVER-YEARRESERVOIR DESCRIPTION INCREMENTAL MARGINS, EX-ITEMS, EXCEEDING 80% SEQUENTIALLY; 70% YEAR-OVER-YEARSHAREHOLDERS APPROVE REDOMESTICATION TO THE U.S.COMPANY ANNOUNCES Q2 2023 QUARTERLY DIVIDENDAMSTERDAM, April 26, 2023 /PRNewswire/ -- Core Laboratories N.V. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported first quarter 2023 revenue of $128,400,000. Core'